Report Phase 1 data for DNL343 in healthy volunteers
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 11 Jan 2021
- Due
- 30 Jun 2021
- Delivered
- May 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Phase 1 healthy subject data on EIF2B activator, DNL343, expected to be available in 1H 2021”
What we found
Evidence strength A What the grades mean
Denali announced in May 2021 that interim data from the Phase 1 study of DNL343 in healthy volunteers showed that safety and biomarker goals were met, fulfilling the commitment before the June 2021 deadline.
-
A Denali Therapeutics Inc. 10-Q filed 2021-08-04
“In May 2021, we announced that based on interim data from the ongoing Phase 1 single- and multiple-ascending-dose study of DNL343 in healthy volunteers, safety and pathway engagement biomarker goals of the study were met.” ✓ confirmed on the page
Market reaction: the shares moved +1.5% against the S&P 500 over the three sessions around the disclosure (3 Aug 2021 to 6 Aug 2021). What this measures
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- DNL343 Phase 1 data
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Denali Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-DNLI-021862 · Corrections policy